SAP stock price crashes 23%, €28bn wiped out as firm warns of Klein(er) revenues, profits ahead due to COVID-19

SAP: Look into the cloud, look around the cloud... you're under. Market: Nope


Europe’s largest software manufacturer, SAP, took a massive hit to its share value this morning cutting its profit and sales outlook for the full financial year, as businesses continued to scale back investments during the COVID-19 pandemic.

At the time of publication, it was trading on the NYSE at $114.52, a drop of $35.16, or 23.49 per cent, from its Friday closing. Other business software stocks, including Oracle and Salesforce, have also experienced dips this morning.

SAP said it expects [PDF]: €8bn to €8.2bn non-IFRS cloud revenue (down from €8.3bn - €8.7bn); €23.1bn - €23.6bn non-IFRS cloud and software revenue (previously €23.4bn - €24bn); €8.1bn to 8.5bn non-IFRS operating profit at constant currencies (previously €8.1bn - 8.7bn).

SAP had already cut its full-year guidance in April, warning that business had slowed during March due to the initial impact of COVID-19.

Suit waves goodbye to train

German-speaking SAP user survey sees S4/HANA upgrade projects either sink or swim as coronavirus cuts into revenue

READ MORE

Meanwhile, for its third quarter, ended September 30, it said revenue had dropped by 4 per cent to €6.535m year-over-year. Operating profit plunged by 12 per cent to €1.473bn.

SAP’s services business unit was the most acutely affected, dropping 16 per cent to €753m. The firm partially attributed this to the closure and subsequent delayed re-opening of training centres, although it noted consulting projects were largely able to continue to proceed without much impact.

Revenue in SAP’s Concur business unit — which handles travel, expense, and invoice management tech — also plunged. sales were down 14 per cent to €357m, which the firm blamed on pandemic-inducted travel restrictions, resulting in lower volumes from “pay-as-you-go” customers. SAP acquired Concur in 2014 for a cool $7bn.

The firm said it "no longer anticipates a meaningful recovery in SAP Concur business travel-related revenues for the remainder of the year 2020."

Software licensing and support is SAP's bread and butter. This sector was down 2 per cent to €5.17bn. The sole bright spot came from SAP’s cloud businesses, which collectively brought in €1.974bn, up 11 per cent.

Trying to put a positive spin on otherwise dismal figures, SAP CEO Christian Klein said in a canned statement:

"COVID-19 has created an inflection point for our customers. The move to the cloud combined with a true business transformation has become a must for enterprises, to gain resiliency and position them to emerge stronger out of the crisis.

"Together with our customers and partners we will co-innovate and reinvent how businesses run in a digital world. SAP will accelerate growth in the cloud to more than €22bn in 2025 and expand the share of more predictable revenue to approximately 85 per cent," he added.

This is a regular refrain from SAP, which has increasingly touted the growth of its cloud business in the face of shrinking licensing and support revenue. This has been bolstered by several strategic investments over the years, including Callidus, which was bought to booster the German firm’s cloud CRM chops. ®

Broader topics


Other stories you might like

  • Google sours on legacy G Suite freeloaders, demands fee or flee

    Free incarnation of online app package, which became Workplace, is going away

    Google has served eviction notices to its legacy G Suite squatters: the free service will no longer be available in four months and existing users can either pay for a Google Workspace subscription or export their data and take their not particularly valuable businesses elsewhere.

    "If you have the G Suite legacy free edition, you need to upgrade to a paid Google Workspace subscription to keep your services," the company said in a recently revised support document. "The G Suite legacy free edition will no longer be available starting May 1, 2022."

    Continue reading
  • SpaceX Starlink sat streaks now present in nearly a fifth of all astronomical images snapped by Caltech telescope

    Annoying, maybe – but totally ruining this science, maybe not

    SpaceX’s Starlink satellites appear in about a fifth of all images snapped by the Zwicky Transient Facility (ZTF), a camera attached to the Samuel Oschin Telescope in California, which is used by astronomers to study supernovae, gamma ray bursts, asteroids, and suchlike.

    A study led by Przemek Mróz, a former postdoctoral scholar at the California Institute of Technology (Caltech) and now a researcher at the University of Warsaw in Poland, analysed the current and future effects of Starlink satellites on the ZTF. The telescope and camera are housed at the Palomar Observatory, which is operated by Caltech.

    The team of astronomers found 5,301 streaks leftover from the moving satellites in images taken by the instrument between November 2019 and September 2021, according to their paper on the subject, published in the Astrophysical Journal Letters this week.

    Continue reading
  • AI tool finds hundreds of genes related to human motor neuron disease

    Breakthrough could lead to development of drugs to target illness

    A machine-learning algorithm has helped scientists find 690 human genes associated with a higher risk of developing motor neuron disease, according to research published in Cell this week.

    Neuronal cells in the central nervous system and brain break down and die in people with motor neuron disease, like amyotrophic lateral sclerosis (ALS) more commonly known as Lou Gehrig's disease, named after the baseball player who developed it. They lose control over their bodies, and as the disease progresses patients become completely paralyzed. There is currently no verified cure for ALS.

    Motor neuron disease typically affects people in old age and its causes are unknown. Johnathan Cooper-Knock, a clinical lecturer at the University of Sheffield in England and leader of Project MinE, an ambitious effort to perform whole genome sequencing of ALS, believes that understanding how genes affect cellular function could help scientists develop new drugs to treat the disease.

    Continue reading

Biting the hand that feeds IT © 1998–2022